Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Current Deferred Revenue (2020 - 2025)

Cytosorbents' Current Deferred Revenue history spans 8 years, with the latest figure at $182000.0 for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $182000.0 for Q4 2025, down 69.46% from a year ago — trailing twelve months through Dec 2025 was $182000.0 (down 69.46% YoY), and the annual figure for FY2025 was $182000.0, down 69.46%.
  • Current Deferred Revenue for Q4 2025 was $182000.0 at Cytosorbents, down from $403000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $1.9 million in Q4 2021 to a low of $182000.0 in Q4 2025.
  • The 5-year median for Current Deferred Revenue is $571014.0 (2024), against an average of $866621.8.
  • The sharpest move saw Current Deferred Revenue surged 167.36% in 2021, then crashed 69.46% in 2025.
  • Year by year, Current Deferred Revenue stood at $1.9 million in 2021, then dropped by 22.11% to $1.5 million in 2022, then decreased by 8.96% to $1.4 million in 2023, then crashed by 56.84% to $596000.0 in 2024, then crashed by 69.46% to $182000.0 in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $182000.0, $403000.0, and $361000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.